Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.65 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1354794 | 0.93 | ADORA2A (0.65) | ADORA2AATMEPHB3KITRAB9A | |
| SCHEMBL14899926 | 0.83 | ADORA2A (0.65) | ADORA2AATMRAB9A | |
| SCHEMBL1354594 | 0.81 | ADORA2A (0.74) | ADORA2AATMKITRAB9A | |
| SCHEMBL1355150 | 0.79 | ADORA2A (0.72) | ADORA2AATMRAB9A | |
| SCHEMBL1355284 | 0.79 | ADORA2A (1.00) | ADORA2AATMRAB9A | |
| SCHEMBL1356242 | 0.78 | ADORA2A (0.70) | ADORA2AATMRAB9A | |
| SCHEMBL27978954 | 0.76 | ADORA2A (0.76) | ADORA2AATMEPHB3RAB9A | |
| SCHEMBL1355495 | 0.75 | ADORA2A (0.73) | ADORA2AATMRAB9A | |
| SCHEMBL1355300 | 0.73 | ADORA2A (0.70) | ADORA2AATMRAB9A | |
| SCHEMBL1355583 | 0.72 | ADORA2A (0.88) | ADORA2AATMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029393-B2 | Adenosine receptor ligands and uses thereof | KALDI PHARMA, SAS (FR) | 2015-05-12 | — | — | US | disclosed |
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | DOMAIN THERAPEUTICS (FR) | 2011-11-24 | — | — | US | disclosed |
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | DOMAIN THERAPEUTICS (FR) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ATM 801/4885EPHB3 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.